Development of [F-18]-Labeled Amyloid Imaging Agents for PET | Zendy

CA Mathis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Development of [F-18]-Labeled Amyloid Imaging Agents for PET

Author(s) -

CA Mathis

Publication year - 2007

Publication title -

osti oai (u.s. department of energy office of scientific and technical information)

Language(s) - English

Resource type - Reports

DOI - 10.2172/903085

Subject(s) - amyloid (mycology) , neuropathology , positron emission tomography , pet imaging , in vivo , β amyloid , neuroscience , medicine , alzheimer's disease , psychology , disease , pathology , biology , microbiology and biotechnology

The applicant proposes to design and synthesize a series of fluorine-18-labeled radiopharmaceuticals to be used as amyloid imaging agents for positron emission tomography (PET). The investigators will conduct comprehensive iterative in vitro and in vivo studies based upon well defined acceptance criteria in order to identify lead agents suitable for human studies. The long term goals are to apply the selected radiotracers as potential diagnostic agents of Alzheimer's disease (AD), as surrogate markers of amyloid in the brain to determine the efficacy of anti-amyloid therapeutic drugs, and as tools to help address basic scientific questions regarding the progression of the neuropathology of AD, such as testing the "amyloid cascade hypothesis" which holds that amyloid accumulation is the primary cause of AD

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research